Better-informed treatment and follow-up.
For investors
Oncology is becoming data-rich. Clinical decisions are still data-poor.
EvoClin builds the infrastructure and proprietary AI that turn fragmented clinical and molecular data into patient-level foresight.
The market shift
More patients. More sequencing. More data hospitals cannot yet use.
Molecular profiling is moving into routine oncology, while clinical and genomic evidence remains fragmented across reports and disconnected systems.
- 01CollectReports, systems, sequencing
- 02HarmonizeOne longitudinal patient history
- 03Extract knowledgeTurn heterogeneous data into usable evidence
- 04AnticipateModel cancer's next move
- 05ActSupport care decisions and planning
Less manual work and clearer priorities.
Better use of capacity and clinical resources.
Commercial path
From workflow utility to predictive oncology at scale.
The data layer drives adoption now. Validation expands the intelligence layer over time.
Beta productHospital pilotsSite validationScalable deployment
Investor information